These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33288660)

  • 21. FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With
    Kim J; Bradford D; Larkins E; Pai-Scherf LH; Chatterjee S; Mishra-Kalyani PS; Wearne E; Helms WS; Ayyoub A; Bi Y; Sun J; Charlab R; Liu J; Zhao H; Liang D; Ghosh S; Philip R; Pazdur R; Theoret MR; Beaver JA; Singh H
    Clin Cancer Res; 2021 Oct; 27(20):5452-5456. PubMed ID: 34045295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
    Kazandjian D; Blumenthal GM; Chen HY; He K; Patel M; Justice R; Keegan P; Pazdur R
    Oncologist; 2014 Oct; 19(10):e5-11. PubMed ID: 25170012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
    Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
    Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
    Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
    Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
    Mathieu L; Shah S; Pai-Scherf L; Larkins E; Vallejo J; Li X; Rodriguez L; Mishra-Kalyani P; Goldberg KB; Kluetz PG; Theoret MR; Beaver JA; Pazdur R; Singh H
    Oncologist; 2021 May; 26(5):433-438. PubMed ID: 33687763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
    Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
    Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer.
    Kepp O; Zitvogel L; Kroemer G
    Oncoimmunology; 2020 Jul; 9(1):1795995. PubMed ID: 32923159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients.
    Aviles P; Altares R; van Andel L; Lubomirov R; Fudio S; Rosing H; Márquez Del Pino FM; Tibben MM; Benedit G; Nan-Offeringa L; Luepke Estefan XE; Francesch A; Zeaiter A; Cuevas C; Schellens JHM; Beijnen JH
    Drug Metab Dispos; 2022 Apr; 50(4):327-340. PubMed ID: 35042701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
    Ragavan M; Das M
    Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
    Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
    Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
    Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
    Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
    Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
    Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
    Khozin S; Blumenthal GM; Jiang X; He K; Boyd K; Murgo A; Justice R; Keegan P; Pazdur R
    Oncologist; 2014 Jul; 19(7):774-9. PubMed ID: 24868098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
    Hanvesakul R; Rengarajan B; Naveh N; Boccuti A; Park JE; Adeyemi A; Caisip C; Jansen JP; Wilson FR
    J Comp Eff Res; 2023 May; 12(5):e220098. PubMed ID: 37079341
    [No Abstract]   [Full Text] [Related]  

  • 36. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.
    Cohen MH; Williams GA; Sridhara R; Chen G; Pazdur R
    Oncologist; 2003; 8(4):303-6. PubMed ID: 12897327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network.
    Sallam M; Wong H; Escriu C
    BMC Pulm Med; 2019 Nov; 19(1):195. PubMed ID: 31675940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Managing Patients With Relapsed Small-Cell Lung Cancer.
    Gong J; Salgia R
    J Oncol Pract; 2018 Jun; 14(6):359-366. PubMed ID: 29894664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.